Cargando…
Serum tumour M2‐pyruvate kinase as a biomarker for diagnosis and prognosis of early‐stage non–small cell lung cancer
Tumour M2‐pyruvate kinase (TUM2‐PK) is up‐regulated in many human cancers. This study was to evaluate the clinical value of serum TUM2‐PK in early‐stage non–small cell lung cancer (NSCLC) patients. A total of 162 consecutive early‐stage NSCLC patients were enrolled and followed up after tumour resec...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335667/ https://www.ncbi.nlm.nih.gov/pubmed/34255923 http://dx.doi.org/10.1111/jcmm.16762 |